News summary

ONL Therapeutics Completes Enrollment in Global Phase 2 GALAXY Trial of Xelafaslatide in Patients with Geographic Atrophy Associated with Dry AMD

Source: PR Newswire • Published: 17 Nov 2026, 13:36

Summarized by Masters of Longevity from PR Newswire.

The global Phase 2 trial enrolled about 324 GA patients to test xelafaslatide.

ONL Therapeutics Completes Enrollment in Global Phase 2 GALAXY Trial of Xelafaslatide in Patients with Geographic Atrophy Associated with Dry AMD
Key Takeaways
  • GALAXY enrolled about 324 patients across three regions.
  • Xelafaslatide is given by intravitreal injection at varied schedules.
  • Topline 48-week efficacy data are expected in Q4 2027.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickCan Doctors Be Trained for the Longevity Era?A new global survey suggests that healthy longevity medicine education can change how physicians think and talk about ageing. But the evidence also highlights how much work remains before a rapidly growing field becomes routine clinical care.